Quick Answer
Tonix Pharmaceuticals Holding Corp. reported Diluted EPS of $14.57 per share (loss) for fiscal year 2025.
Tonix Pharmaceuticals Holding Corp. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$14.57 | +91.7% |
| 2024 | -$176.60 | +98.8% |
| 2023 | -$14720.25 | -73464.5% |
| 2022 | -$20.01 | -147.0% |
| 2021 | -$8.10 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.59 | +84.2% | +7.0% |
| June 30, 2025 | -$3.86 | +99.8% | -35.9% |
| March 31, 2025 | -$2.84 | +99.5% | +87.5% |
| September 30, 2024 | -$22.68 | +41.3% | +98.8% |
| June 30, 2024 | -$1920.85 | -3801.8% | -258.6% |
| March 31, 2024 | -$535.72 | -16589.1% | -1286.8% |
| September 30, 2023 | -$38.63 | -811.1% | +21.5% |
| June 30, 2023 | -$49.23 | -544.4% | -1433.6% |
- Tonix Pharmaceuticals Holding Corp. showed an increase of +91.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Tonix Pharmaceuticals Holding Corp.’s diluted eps has declined by 79.9% (from $8.10 per share (loss) to $14.57 per share (loss)).
- The most recent figure is from Tonix Pharmaceuticals Holding Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: